SCOPUS 정보 검색 플랫폼

Journal of Health Economics

Volumn 10, Issue 2, 1991, Pages 107-142

Cost of innovation in the pharmaceutical industry

(4) DiMasi, Joseph A a Hansen, Ronald W b Grabowski, Henry G c Lasagna, Louis a

a TUFTS UNIVERSITY (United States)

b UNIVERSITY OF ROCHESTER (United States)

c DUKE UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; DRUG INDUSTRY; FINANCE; REVIEW;

COSTS AND COST ANALYSIS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMAN; SUPPORT, NON-U.S. GOV'T; UNITED STATES;

EID: 0025868362 PISSN: 01676296 EISSN: None Source Type: Journal
DOI: 10.1016/0167-6296(91)90001-4 Document Type: Article

Times cited : (482)

References (35)

1
- 0000368475
- Qualitative response models: A survey
- (1981) Journal of Economic Literature , vol.19 , pp. 1483-1536
- Amemiya¹

2
- 0011780755
- Research and Development Costs and Returns: The U.S. Pharmaceutical Industry
- (1972) Journal of Political Economy , vol.80 , Issue.1 , pp. 70-85
- Baily¹

3
- 73949120540
- The changing costs and risks of pharmaceutical innovation
- J.D. Cooper, American University, Washington, DC
- (1970) The economics of drug innovation , pp. 109-124
- Clymer¹

4
- 0003667275
- Chapman and Hall, London
- (1984) Analysis of survival data
- Cox¹ Oakes²

5
- 84909811016
- Halving the pain of budget balance
- May 28
- (1988) Wall Street Journal , pp. 24
- Feldstein¹

6
- 84909783678
- Lilly estimates ‘3,300 person years’ go into development of successful new molecular entity; current antibiotic project is requiring 10,000 patients
- (1989) F-D-C Reports: The Pink Sheet , vol.51 , Issue.51-52 & , pp. 14

7
- 0038659516
- An analysis of U.S. international competitiveness in pharmaceuticals
- (special issue), Spring
- (1989) Managerial and Decision Economics , pp. 27-33
- Grabowski¹

8
- 84909763340
- Innovation and international competitiveness in pharmaceuticals
- A. Heertje, M. Perlman, University of Michigan Press, Ann Arbor
- (1990) Evolving technology in market structure: Studies in Schumpeterian economics , pp. 167-185
- Grabowski¹

9
- 0002492663
- A sensitivity analysis of expected profitability of pharmaceutical research and development
- (1982) Managerial and Decision Economics , vol.3 , Issue.1 , pp. 36-40
- Grabowski¹ Vernon²

10
- 0001647605
- A New Look at the Returns and Risks to Pharmaceutical R&D
- (1990) Management Science , vol.36 , Issue.7 , pp. 804-821
- Grabowski¹ Vernon²

11
- 0018049731
- Estimating the effects of regulation on innovation: An international comparative analysis of the pharmaceutical industry
- (1978) Journal of Law and Economics , vol.21 , Issue.1 , pp. 133-163
- Grabowski¹ Vernon² Thomas³

12
- 0002914798
- The pharmaceutical development process: Estimates of current development costs and times and the effects of regulatory changes
- R.I. Chien, Lexington Books, Lexington, MA
- (1979) Issues in pharmaceutical economics , pp. 151-187
- Hansen¹

13
- 84909766762
- Pharmaceutical development costs by therapeutic categories
- March
- (1980) University of Rochester Graduate School of Management Working Paper No. GPB-80-6
- Hansen¹

14
- 0022596773
- A closer look at the returns and risks of pharmaceutical R&D
- (1986) Journal of Health Economics , vol.5 , pp. 153-177
- Joglekar¹ Paterson²

15
- 0002582930
- Price Indexes for R and D Inputs, 1969–1983
- (1987) Management Science , vol.33 , Issue.1 , pp. 124-129
- Mansfield¹

16
- 0002513817
- New drug development in the United States, 1963–1984
- (1988) Clinical Pharmacology and Therapeutics , vol.43 , pp. 15-27
- Mattison¹ Trimble² Lasagna³

17
- 0002297105
- Conditional logit analysis of qualitative choice behavior
- P. Zarembka, Academic Press, New York
- (1974) Frontiers in econometrics , pp. 105-142
- McFadden¹

18
- 84909781521
- The return on investment of the innovative pharmaceutical firm
- J.D. Cooper, American University, Washington, DC
- (1970) The economics of drug innovation , pp. 125-138
- Mund¹

19
- 0040160105
- National Academy Press, Washington, DC
- (1983) The competitive status of the U.S. pharmaceutical industry
- National Academy of Engineering¹

20
- 84909806435
- PMA, Washington, DC
- (1987) PMA statistical fact book
- Pharmaceutical Manufacturers Association¹

21
- 84909775694
- PMA, Washington, DC, various years
- (1968) Annual survey report
- Pharmaceutical Manufactures Association¹

22
- 84909777921
- FDA regulations and their influence on future research and development
- (1974) Research Management , pp. 18-20
- Sarett¹

23
- 36048998937
- Development Cost: Determinants and Overruns
- (1972) The Journal of Business , pp. 347-374
- Schnee¹

24
- 0021721477
- Success rates in the United States drug development system
- (1984) Clinical Pharmacology and Therapeutics , vol.36 , pp. 574-583
- Sheck¹ Cox² Davis³ Trimble⁴ Wardell⁵ Hansen⁶

25
- 0003535376
- American Enterprise Institute, Studies in Health Policy, Washington, DC
- (1983) Competition in the pharmaceutical industry
- Statman¹

26
- 84909821629
- Spare the rod and spoil the industry: Vigorous competition and vigorous regulation promote global competitive advantage
- presented at the, June, Charlottesville, VA.
- (1990) International Joseph Schumpeter Society Meetings
- Thomas¹

27
- 84909809116
- The outcome of research on new molecular entities commencing clinical research in the years 1976–1978
- Food and Drug Administration, Rockville, MD
- (1988) Office of Planning and Evaluation Study , vol.77
- Tucker¹ Blozan² Coppinger³

28
- 84909767842
- U.S. Government Printing Office, Washington, DC
- (1986) The biomedical research and development price index: Revised and updated estimates
- U.S. Bureau of Economic Analysis, Government Division,¹

29
- 84909800844
- Prescription drug price increases
- U.S. Government Printing Office, Washington, DC
- (1985) 99th Congress, First Session, July 15, 1985
- U.S. Congress, House, Subcommittee on Health and the Environment of the Committee on Energy and Commerce,¹

30
- 84909785040
- Medical devices and drug issues
- U.S. Government Printing Office, Washington, DC
- (1987) 100th Congress, First Session, April 27, 1987 and May 4, 1987
- U.S. Congress, House, Subcommittee on Health and the Environment of the Committee on Energy and Commerce,¹

31
- 79959535243
- Prescription drug prices: Are we getting our money's worth?
- U.S. Government Printing Office, Washington, DC
- (1989) Majority staff report
- U.S. Congress, Senate, Special Committee on Aging,¹

32
- 84909772719
- Justification of appropriation estimates for committee on appropriations
- U.S. Public Health Service, Hyattsville, MD
- (1990) Food and Drug Administration , vol.10
- U.S. Department of Health and Human Services¹

33
- 5844349649
- The pharmaceutical research and development decision process
- R.B. Helms, American Enterprise Institute, Washington, DC
- (1981) Drugs and health: Issues and policy objectives
- Wiggins¹

34
- 0002619673
- Pharmaceutical Manufacturers Association, Washington, DC, June
- (1987) The cost of developing a new drug
- Wiggins¹

35
- 0002598854
- Reviewing the bidding: R&D costs and profitability of new chemical entities
- (1989) Journal of Research in Pharmaceutical Economics , vol.1 , Issue.3 , pp. 49-65
- Woltman¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.